

Comment [S1]: Antibiotic resistance in *Pseudomonas aeruginosa* and *Acinetobacter baumannii* isolates from the Conakry region, Guinea

Study of antibiotic resistance in *Pseudomonas aeruginosa* and *Acinetobacter baumannii* species isolated in the Conakry region, Guinea

Abstract

Objectives: This study aimed to investigate the antibiotic resistance of *Pseudomonas aeruginosa* and *Acinetobacter baumannii* strains isolated in the Conakry region from 2022 to 2024.

Study type: This cross-sectional study was conducted from 2022 to 2024 in the Conakry region.

Study location and duration: National Institute of Public Health (INSP), Biomar-24 medical biology laboratory, and Donka University Hospital Center, between 2022 and 2024.

Methods: Bacterial identification and antibiotic susceptibility testing were performed using VITEK 2 Compact, following EUCAST guidelines.

Results: Eighty bacterial strains were isolated, of which 57.5% were *Acinetobacter baumannii* and 42.5% were *Pseudomonas aeruginosa*. Regarding the origin of the samples, urine samples were the most common at 57.5%, followed by pus (15%) and blood (13.75%). There was high resistance to ticarcillin (43.75%), ceftazidime (32.5%), and piperacillin-tazobactam (31.25%), and low resistance to colistin (5%) and imipenem (7.52%), making them the most effective antibiotics. In addition, there was notable resistance to tobramycin (33.75%), especially in *Acinetobacter baumannii*.

Conclusion: This study highlights an alarming frequency of resistance. It calls for a strengthening of surveillance policies and better management of antibiotics in Guinea.

Keywords: resistance, *Pseudomonas aeruginosa*, *Acinetobacter baumannii*, Conakry.

- Comment [S2]:** has become
- Comment [S3]:** (MDR)
- Comment [S4]:** Italic
- Comment [S5]:** cause
- Comment [S6]:** annually
- Comment [S7]:** (*Acinetobacter baumannii* , *Pseudomonas aeruginosa*)
- Comment [S8]:** were associated with
- Comment [S9]:** Italic
- Comment [S10]:** Italic
- Comment [S11]:** reported/observed
- Comment [S12]:** (*Acinetobacter baumannii* , *Pseudomonas aeruginosa*)
- Comment [S13]:**
- Comment [S14]:** Correct the placement of references so that the names of authors are not repeated twice.
- Comment [S15]:** Reworded the last part to make the proportions of each species clearer.
- Comment [S16]:** (*Acinetobacter baumannii* , *Pseudomonas aeruginosa*)
- Comment [S17]:** remain limited
- Comment [S18]:** characterize
- Comment [S19]:** Edit the conclusion to enhance understanding... support the development... to be more formal and streamlined.
- Comment [S20]:** This cross-sectional study was conducted in the Conakry region over a three-year period, from 2022 to 2024.
- Comment [S21]:** West African country ↵
- Comment [S22]:** comprising
- Comment [S23]:** Modify the name of the reference to the official wording (Guinée – Politique Nationale de Santé, August 2015)
- Comment [S24]:** operating under the supervision of
- Comment [S25]:** whose responsibilities include
- Comment [S26]:** is equipped to diagnose
- Comment [S27]:** and medicines, performing biological diagnostics, and conducting public health research (Lesage, 2025). Its bacteriology unit, ... [1] ed as a benchmark for antimicrobial
- Comment [S28]:** Institute (INSP), the University ... [2]
- Comment [S29]:** The study included all patients ... [3]
- Comment [S30]:** All patients who attended the ... [4]

INTRODUCTION

Antimicrobial resistance (AMR) is now a major global public health issue, causing more than 700,000 deaths per year (Krug, 2023), particularly in developing countries (Pragasam et al., 2016; Thompson, 2024). Infections caused by multidrug-resistant bacterial pathogens are often associated with high morbidity and mortality (Herindrainy, 2018). Among these pathogens of concern, *Pseudomonas aeruginosa* and *Acinetobacter baumannii* are prominent, with mortality rates of 24.5% and 30.5% within 90 days of infection (Vivo et al., 2022) and their ability to rapidly develop resistance to multiple classes of antibiotics (Organization, 2022). According to the World Health Organization (WHO), without effective measures, AMR could be responsible for more than 10 million deaths per year by 2050 (O'Neill, 2016). Furthermore, in 2019, carbapenem-resistant *A. baumannii* and *P. aeruginosa* were responsible for 57,700 and 38,100 deaths worldwide, respectively (Antimicrobial Resistance Collaborators, 2022). In Ethiopia in 2022, Araya et al (Araya et al., 2023) found an overall multi-resistance rate of 73.7% and 58.9% for *A. baumannii* and *P. aeruginosa*, respectively. In Mali in 2022, Doumbia et al (Doumbia, 2022) reported multidrug resistance in 44.66% of isolated germs, with 33.01% of *Acinetobacter baumannii* and 11.65% of *Pseudomonas aeruginosa*. In Guinea, epidemiological data on the prevalence and resistance profiles of *Pseudomonas aeruginosa* and *Acinetobacter baumannii* are still limited. In this context, the present study aimed to investigate the antibiotic resistance profile of these two bacterial species isolated in the Conakry region, to better understand their local epidemiology and contribute to the development of more effective therapeutic and prevention strategies in Guinean healthcare facilities.

MATERIAL AND METHODS

Type and duration of study

This was a cross-sectional study conducted in the Conakry region over a three-year period from 2022 to 2024.

General context

The Republic of Guinea is a country in West Africa, bordered by Guinea-Bissau, Senegal, Mali, Ivory Coast, Liberia, and Sierra Leone. Its population is estimated at around 14.5 million. The Guinean healthcare system is pyramid-shaped, with health centers at the base, regional hospitals, and national hospitals for more serious cases (guinee - politique nationale sante aout 2015).

Specific setting

The bacteriology unit of the laboratory department of the Guinea National Public Health Institute (INSP) served as the setting for this study. The INSP is a public institution under the supervision of the Guinean Ministry of Health and Public Hygiene. Its role is to monitor and control the quality of food products (testing for toxins) and medicines, carry out biological diagnostics, and conduct public health research (Lesage, 2025). Its bacteriology unit, a benchmark in antimicrobial resistance surveillance in Guinea, has the capacity to diagnose bacterial infectious diseases and conducts external quality assessments of various bacteriology laboratories at the national level, as well as training laboratory staff through professional coaching and training sessions.

Site selection

We selected three laboratories such as Guinea National Public Health (INSP), University Hospital Center Donka, and Biomedical laboratory Biomar-24, in the Conakry region because they have the automated platform (VITEK 2 Compact) for performing identification and sensitivity tests. Regional laboratories that do not have this automated platform were not selected.

Study population

The study included all patients who visited the laboratories and in whom Gram-negative non-fermentative bacteria were identified during the study period.

Inclusion criteria

All patients who visited the selected laboratories for a cyto-bacteriological examination during the study period were included.

Comment [S31]: revealed

Comment [S32]: that did

Comment [S33]: from the study

Comment [S34]: The study variables included sociodemographic characteristics (age and sex), the isolated bacterial strains (*Pseudomonas aeruginosa* and *Acinetobacter baumannii*), the type of clinical sample (blood, pus, urine, semen, cerebrospinal fluid, and pleural fluid), and the antibiotics tested, which included beta-lactams, aminoglycosides, and fluoroquinolones/other agents.

Comment [S35]: For the cytobacteriological tests, biological specimens including pus, urine, semen, cerebrospinal fluid, blood, and pleural fluid were analyzed. The microbiological analysis began with microscopic examination of fresh samples, followed by Gram staining of prepared slides. Bacterial cultures were grown on various media, including CLED agar, MacConkey agar, and chocolate agar. After inoculation, the cultures were incubated for 18 hours. Monomorphic colonies isolated from the cultures were Gram-stained to confirm purity.

Bacterial identification, antimicrobial susceptibility testing, and determination of minimum inhibitory concentrations (MICs) were performed using the automated VITEK 2 Compact system. The European Committee for Antimicrobial Susceptibility Testing (EUCAST) guidelines were used to select the antibiotics for testing and to determine their MICs (Giske et al., 2022)

Comment [S36]: The data collected using

Comment [S37]: proportions

Comment [S38]: summarized and presented

Comment [S39]: was approved by

Comment [S40]: In accordance with

Comment [S41]: were

Comment [S42]: from various clinical sources

Comment [S43]: were included in our study population

Comment [S44]: italic

Comment [S45]: italic

Comment [S46]: italic

Exclusion criteria

Patients whose identification tests reported bacterial strains not belonging to the Gram-negative non-fermentative bacteria family were excluded.

Study variables

The study variables were sociodemographic (age, sex), isolated bacterial strain (*Pseudomonas aeruginosa* and *Acinetobacter baumannii*), sample type (blood, pus, urine, semen, cerebrospinal fluid, and pleural fluid), and antibiotics tested (beta-lactams, aminoglycosides, and fluoroquinolones/others).

Laboratory procedures

For the cytobacteriological tests, biological materials such as pus, urine, semen, cerebrospinal fluid, blood, and pleural fluid were tested.

For the microbiological analysis itself, cytobacteriological tests on the samples were performed through microscopic observation in fresh state followed by Gram staining of the slides prepared for this purpose. Bacterial cultures were grown on various culture media such as Cled agar, MacConkey agar, and chocolate agar. After inoculation on the culture media, an incubation period of 18 hours in an incubator was allowed. Isolated monomorphic colonies from the cultures were stained using the Gram staining method to confirm the purity of the colonies. The automatic "VITEK 2 Compact" method was used for bacterial identification, antibiogram, and determination of minimum inhibitory concentrations (MIC). The European Committee for Antimicrobial Susceptibility Testing (EUCAST) (Giske et al., 2022) served as our guide for selecting the antibiotics to be tested and determining their MICs.

Data analysis

Our data collected using Microsoft Excel was analyzed using SPSS software, version 26. Sociodemographic characteristics, different proportions, and antibiotic resistance profiles were presented in tables and figures.

Ethical considerations

The Institutional Review Board of the National Institute of Public Health authorized this study (Approval No. 07/Lab/INSP/2025). In alignment with national ethical guidelines, all data were anonymized to ensure the protection of participant confidentiality and used exclusively for scientific purposes.

RESULTS AND DISCUSSION

Figure 1 shows that a total of 7,629 samples from all causes were received in the three bacteriology laboratories (INSP, Biomar-24, and CHU Donka) included in the study in the Conakry region. Of those that tested positive, 80 constituted our study population and consisted of 57.5% *Acinetobacter baumannii* and 42.5% *Pseudomonas aeruginosa* between 2022 and 2024.

In addition, the emergence of multidrug-resistant *Acinetobacter* isolates is a major concern in hospitals in many parts of the world (Papp-Wallace et al., 2011). Our results corroborate those found by Doumbia et al. (Doumbia, 2022) with 54.37% and 45.63% respectively.




Figure I: Flow chart showing the isolation of strains in Conakry laboratories from 2022 to 2024.

Comment [S47]: indicate that males predominated

Comment [S48]: The results indicate that males predominated, with a male-to-female ratio (M/F) of 1.42. The most represented age group was over 50 years, accounting for 32.5% of the study population, followed by the 36–50 years age group (28.7%). The mean age was 41.05 ± 20.97 years.

Table I shows that males were in the majority, with a ratio (M/F) = 1.42. The most represented age group was over 50 years old, with 32.5%, followed by the 36 to 50 age group (28.7%), with a mean ± standard deviation of 41.05 ± 20.97 years.

Table I: Distribution of patients according to sociodemographic characteristics

Variables	Frequency	Percentage
Sex		
Masculine	47	58,8
Feminine	33	41,3
Age (years)		
< 10	8	10,0
11 -18	6	7,5
19 -35	17	21,3
36 – 50	23	28,7
> 50	26	32,5
Mean ± Standard Deviation : 41,05 ± 20,97 ans		

Table II shows that, in general, these two species were predominant in urine samples, followed by pus, with respective frequencies of 57.5% and 15%. These results corroborate those reported by Makanera A. et al. (Makanera et al., 2017) but are higher than those found in India (Ravella Venkatasubramanyam et al., 2024). The other types of samples in which *P. aeruginosa* and *A. baumannii* were isolated were blood (13.75%), cerebrospinal fluid (3.75%), and urinary catheter (3.75%), respectively. However, the *P. aeruginosa* strain was also detected in puncture fluid and semen samples, while *A. baumannii* was isolated in an ascites fluid sample.

Comment [S49]: The results show that, overall, these two species were most frequently isolated from urine samples, followed by pus, with respective frequencies of 57.5% and 15%. These findings are consistent with those reported by Makanera et al. (2017) but higher than the rates observed in India (Ravella Venkatasubramanyam et al., 2024). Other sample types in which *P. aeruginosa* and *A. baumannii* were detected included blood (13.75%), cerebrospinal fluid (3.75%), and urinary catheter samples (3.75%). Additionally, *P. aeruginosa* was isolated from puncture fluid and semen samples, while *A. baumannii* was detected in an ascitic fluid sample.

Table II: Distribution of *P. aeruginosa* and *A. baumannii* strains isolated according to the type of samples tested in laboratories from 2022 to 2024.

Type of samples	Isolated bacterial strains		Total N=80
	<i>Acinetobacter baumannii</i> (n=46)	<i>Pseudomonas aeruginosa</i> (n=34)	
CSF	2 (4,34)	1 (2,94)	3 (3,75)
Ascites fluid	1 (2,17)	0 (0,0)	1 (1,25)
Puncture fluid	0 (0,0)	2 (5,88)	2 (2,5)
Pus	1 (2,17)	11 (32,35)	12 (15,0)
Blood	9 (19,56)	2 (5,88)	11 (13,75)
Semen	0 (0,0)	2 (5,88)	2 (2,5)
Urine	32 (69,56)	14 (41,17)	46 (57,5)
Urinary catheter	1 (2,17)	2 (5,88)	3 (3,75)

Table III shows that the highest rates of resistance to beta-lactams were found in ticarcillin and ceftazidime, followed by piperacillin + tazobactam, with varying frequencies of 43.75%, 32.5%, and 31.25%, respectively. In contrast, in Ethiopia (Mekonnen et al., 2021) and Uganda (Agaba et al., 2017), resistance rates of 87.5% and 80% were observed with piperacillin-tazobactam, respectively. With regard to *Pseudomonas aeruginosa*, similar resistance (32%) to piperacillin-tazobactam was observed in India (Ravella Venkatasubramanyam et al., 2024) and high resistance (69%) to ceftazidime was reported by another study in Uganda (Kateete et al., 2016). Imipenem was the most active molecule on both strains, with only 7.52% resistance.

Comment [S50]: ceftazidime, followed by piperacillin-tazobactam, with respective frequencies of 43.75%, 32.5%, and 31.25%. In contrast, higher resistance rates to piperacillin-tazobactam were reported in Ethiopia (87.5%) (Mekonnen et al., 2021) and Uganda (80%) (Agaba et al., 2017). Regarding *Pseudomonas aeruginosa*, similar resistance to piperacillin-tazobactam (32%) was observed in India (Ravella Venkatasubramanyam et al., 2024), while a higher resistance rate (69%) to ceftazidime was reported in Uganda (Kateete et al., 2016). Imipenem was the most effective antibiotic against both strains, with only 7.52% resistance.

Comment [S51]: Regarding aminoglycosides, an overall resistance rate of 33.75% to tobramycin was observed, including 43.47% in *Acinetobacter baumannii* and 20.58% in *Pseudomonas aeruginosa*. Low resistance to amikacin was noted for both *A. baumannii* and *P. aeruginosa*, in contrast to the rates reported in Ethiopia, which were 12.5% and 11.1%, respectively (Mekonnen et al., 2021).

Comment [S52]: Regarding fluoroquinolones, a resistance frequency of 28.75% to ciprofloxacin and 12.5% to ofloxacin was observed. Our findings are comparable to those reported by Doumbia et al. (2022) in Mali, who observed resistance rates of 48.94% and 34.04%, respectively. Additionally, 25% of our isolates were resistant to the combination of trimethoprim and sulfamethoxazole. These results differ from those reported by Makanera et al. (2019) and Odjadjare et al. (2012).

Comment [S53]: Nearly 90% of strains in previous studies were reported to be resistant to this combination (Makanera et al., 2019; Odjadjare et al., 2012). In our study, the lowest resistance was observed with colistin, consistent with the findings of Ravella et al. (2024) and Jiménez et al. (2018), with resistance rates of approximately 5%. These differences may be explained, in part, by variations in sample size. Furthermore, the higher levels of resistance observed for ticarcillin, ceftazidime, and piperacillin-tazobactam could be attributed to the excessive and inappropriate use of these antibiotics in the Conakry region, as antibiotic policies and mechanisms for controlling antimicrobial use are often poorly enforced in Guinea.

Regarding aminoglycosides, we observed an overall resistance of 33.75% to tobramycin, including 43.47% resistance in *A. baumannii* and 20.58% in *P. aeruginosa*. Low resistance to amikacin was observed for *Acinetobacter baumannii* and *Pseudomonas aeruginosa*, unlike the rates observed in Ethiopia, which were 12.5% and 11.1%, respectively (Mekonnen et al., 2021).

About fluoroquinolones, a resistance frequency of 28.75% to ciprofloxacin followed by 12.5% to ofloxacin was obtained. Our results are similar to those reported by Doumbia et al. (Doumbia, 2022) in their study in Mali, with frequencies of 48.94% and 34.04%, respectively. In addition, a quarter of our strains were resistant to the combination of trimethoprim and sulfamethoxazole. These results differ from those reported by Makanera A. et al (Makanera et al., 2019) and Odjadjare et al (Odjadjare et al., 2012), who found that nearly 90% of their strains were resistant to this combination. The lowest resistance was observed with colistin. Our results are like those of Ravella V. et al (Ravella Venkatasubramanyam et al., 2024) and Jiménez et al (Jiménez-Guerra et al., 2018), with a resistance rate of around 5%. These differences could be explained by the variation in sample size on the one hand. Furthermore, the higher level of resistance to ticarcillin, ceftazidime, and piperacillin-tazobactam could be linked to the excessive and inappropriate use of these antibiotics in the Conakry region, as antibiotic policies and mechanisms for controlling the use of antimicrobials in Guinea are not respected in most cases.

Table III: Antibiotic resistance of *A. baumannii* and *P. aeruginosa* strains isolated in laboratories from 2022 to 2024.

Antiotic families	<i>Acinetobacter baumannii</i>	<i>Pseudomonas aeruginosa</i>	Total n=80
	Resistance (%) n=46	Resistance (%) n=34	
Bêta-lactamin			
Piperacillin + Tazobactam	16 (34,78)	9 (26,47)	25 (31,25)
Ticacillin	22 (47,83)	13 (38,24)	35 (43,75)
Ceftazidim	17 (36,95)	9 (26,47)	26 (32,5)
Imipénèm	5 (10,87)	1 (2,94)	6 (7,50)
Aminosides			
Amikacin	2 (4,35)	3 (8,82)	5 (6,25)
Gentamycin	18 (39,13)	4 (11,76)	22 (27,5)
Tobramycin	20 (43,47)	7 (20,58)	27 (33,75)
Fluoroquinolones and others			
Ciprofloxacin	17 (36,95)	6 (17,64)	23 (28,75)
Ofloxacin	7 (15,21)	3 (8,82)	10 (12,5)
Colistin	2 (4,34)	2 (5,88)	4 (5,0)
Nitrofurantoine	4 (8,69)	2 (5,88)	6 (7,50)
Triméthoprim/Sulfaméthoxazole	19 (41,30)	1 (2,94)	20 (25,0)

CONCLUSION

The study conducted on strains of *Acinetobacter baumannii* and *Pseudomonas aeruginosa* isolated in the Conakry region revealed a high level of antibiotic resistance. These results confirm the growing threat posed by these non-fermentative Gram-negative bacteria, known for their ability to develop multiple resistances and cause serious nosocomial infections.

Considering these results, it is imperative to strengthen microbiological surveillance, rationalize the use of antibiotics, and work to implement local programs to combat resistance. This study provides a useful database to guide clinical practices and contributes to a coordinated response to antibiotic resistance in the Conakry region.

Comment [S54]: The present study on *Acinetobacter baumannii* and *Pseudomonas aeruginosa* strains isolated in the Conakry region revealed a high level of antibiotic resistance. These findings underscore the growing threat posed by these non-fermentative Gram-negative bacteria, which are known for their capacity to develop multiple resistances and cause severe nosocomial infections.

In light of these results, it is imperative to strengthen microbiological surveillance, promote the rational use of antibiotics, and implement local programs to combat antimicrobial resistance. This study provides a valuable database to inform clinical practice and supports a coordinated response to antibiotic resistance in the Conakry region.

Comment [S55]: The sources need to be updated and increased in number because they do not cover the research.

References

- Agaba, P., Tumukunde, J., Tindimwebwa, J.V.B., Kwizera, A., 2017. Nosocomial bacterial infections and their antimicrobial susceptibility patterns among patients in Ugandan intensive care units: a cross sectional study. *BMC Res. Notes* 10, 349. <https://doi.org/10.1186/s13104-017-2695-5>
- Antimicrobial Resistance Collaborators, 2022. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *Lancet London. Engl. Rev.* 399, 629–655. [https://doi.org/10.1016/S0140-6736\(21\)02724-0](https://doi.org/10.1016/S0140-6736(21)02724-0)
- Araya, S., Gebreyohannes, Zenebe, Tadlo, Getachew, Gessew, Gebreab Teklebirhan, and Negesso, A.E., 2023. Epidemiology and Multidrug Resistance of *Pseudomonas aeruginosa* and *Acinetobacter baumannii* Isolated from Clinical Samples in Ethiopia. *Infect. Drug Resist.* 16, 2765–2773. <https://doi.org/10.2147/IDR.S4>
- Doumbia, A., 2022. STUDY OF ANTIBIOTICS RESISTANCE OF "Pseudomonas aeruginosa and Acinetobacter baumannii" SPECIES ISOLATED FROM JANUARY 2020 TO DECEMBER 2020 IN A PRIVATE LABORATORY IN BAMAKO (ON A PERIOD OF 12 MONTHS) (PhD Thesis). USTTB.
- Giske, C.G., Turnidge, J., Canton, R., Kahlmeter, G., 2022. Update from the European Committee on Antimicrobial Susceptibility Testing (EUCAST). *J. Clin. Microbiol.* 60, e00276-2 <https://doi.org/10.1128/jcm.00276-21>
- guinea _ national_health_policy_august_2015.pdf, n.d.
- Herindrainy, P., 2018. Epidemiology and mother-child transmission of extended-spectrum beta-lactamase-producing enterobacteria (E-BLSE) in Madagascar. (phdthesis). Paris Saclay University (COMUE).
- <http://dx.doi.org/10.1037/0021-843X.101.1.13> Jimenez-Guerra, G., Heras-Cañas, V., Gutierrez-Soto, M., del Pilar Aznarte-Padial, M., Exposito-Ruiz, M., Navarro-Mari, J.M., Gutierrez-Fernandez, J., *Pseudomonas aeruginosa*: evolution of antimicrobial resistance and therapeutic alternatives. *J. Med. Microbiol.* 67, 790–797. <https://doi.org/10.1099/jmm.0.000742>
- Carbapenem resistant *Pseudomonas aeruginosa* and *Acinetobacter baumannii* at Mulago Hospital in Kampala, Uganda (2007–2009). *SpringerPlus* 5, 1308. <https://doi.org/10.1186/s40064-016-2986-7>
- Krug, A., 2023. Antimicrobial Resistance.
- Lesage, D.J., 2025. The Guinean National Institute of Public Health: A Pillar for Public Health in West Africa [WWW Document]. *Pharm. KOJ*. URL <https://www.pharmaciekoj.com/articles/linsp-de-guinee/> (accessed 5.27.25).
- Makanera, A., Conde, Mariam, Diallo, M.A., Camara, D., Conde, Mariama, Barry, A.O., Diakite, T., 2017. Susceptibility Profile of *Sphingomonas paucimobilis* Strains Isolated from Various Pathological Products at the Sino-Guinean Friendship Hospital Kipe/Conakry (Guinea). *Sci. Vie Terre Agron.* 5.

- Makanera, A., Sidibe, S., Camara, A., Camara, L., Conde, M., Diallo, M., Conde, M., Diakite, T., Camara, D., Barry, A., Sy, O., 2019. Diversity and antibiotic susceptibility of different *Pseudomonas* species at the Sino-Guinean Friendship Hospital, Kipé/Conakry. *Rev. Malienne Infect. Microbiol.* 14, 14–21. <https://doi.org/10.53597/remim.v14i2.1364>
- Mekonnen, H., Seid, A., Fenta, G.M., Gebrecherkos, T., 2021. Antimicrobial resistance profiles and associated factors of *Acinetobacter* and *Pseudomonas aeruginosa* nosocomial infection among patients admitted at Dessie comprehensive specialized Hospital, North-East Ethiopia. A cross-sectional study. *PLOS ONE* 16, e0257272. <https://doi.org/10.1371/journal.pone.0257272>
- Odjadjare, E.E., Igbinosa, E.O., Mordi, R., Igere, B., Igeleke, C.L., Okoh, A.I., 2012. Prevalence of Multiple Antibiotics Resistant (MAR) *Pseudomonas* Species in the Final Effluents of Three Municipal Wastewater Treatment Facilities in South Africa. *Int. J. Approx. Res. Audience. Health* 9, 2092–2107. <https://doi.org/10.3390/ijerph9062092>
- O'Neill, J., 2016. Tackling drug-resistant infections globally: final report and recommendations. Organization, W.H., 2022. Global antimicrobial resistance and use surveillance system (GLASS) report 2022. World Health Organization.
- Papp-Wallace, K.M., Endimiani, A., Taracila, M.A., Bonomo, R.A., 2011. Carbapenems: Past, Present, and Future. *Antimicrob. Agents Chemother.* 55, 4943–4960. <https://doi.org/10.1128/aac.00296-11>
- Pragasam, A., Vijayakumar, S., Bakthavatchalam, Y., Kapil, A., Das, B., Ray, P., Gautam, V., Sistla, S., Parija, S., Wallia, K., Ohri, V., Anandan, S., Veeraraghavan, B., 2016. Molecular characterization of antimicrobial resistance in *Pseudomonas aeruginosa* and *Acinetobacter baumannii* during 2014 and 2015 collected across India. *Indian J. Med. Microbiol.* 34, 433–441. <https://doi.org/10.4103/0255-0857.195376>
- Ravella Venkatasubramanyam, N., Easwaran, S., Prabhakaran, N., 2024. Retrospective Analysis of Antimicrobial Resistance Trends in *Pseudomonas aeruginosa* and *Acinetobacter baumannii*. *Cureus* 16, e69166. <https://doi.org/10.7759/cureus.69166>
- Thompson, L., 2024. The Impact of Antimicrobial Resistance on Public Health: Challenges and Strategic Responses. *Insight Epidemiol. Ed Fr.* 1.
- Vivo, A., Fitzpatrick, M.A., Suda, K.J., Jones, M.M., Perencevich, E.N., Rubin, M.A., Ramanathan, S., Wilson, G.M., Evans, M.E., Evans, C.T., 2022. Epidemiology and outcomes associated with carbapenem-resistant *Acinetobacter baumannii* and carbapenem-resistant *Pseudomonas aeruginosa*: a retrospective cohort study. *BMC Infect. Say.* 22, 491. <https://doi.org/10.1186/s12879-022-07436-w>

Annex

Table IV shows that, more than 60% of the samples were tested at the bacteriology laboratory of the Donka University Hospital Center, followed by those tested at the Biomar-24 medical biology

laboratory and the Guinea National Public Health Institute, with proportions of 25.0% and 7.5%, respectively. The percentage of bacterial species detected varied from one laboratory to another.

Table IV: Distribution of bacterial strains isolated in different analytical laboratories from 2022 to 2024.

Analytical laboratories	Isolated bacterial strains		
	<i>A. baumannii</i>	<i>P. aeruginosa</i>	Total
Biomar-24	7 (8,75)	13 (16,25)	20 (25,0)
INSP-Guinée	1 (1,25)	5 (6,25)	6 (7,5)
CHU Donka	38 (47,5)	16 (20,0)	54 (67,5)

UNDER PEER REVIEW

20/09/2025 05:11:00 **SSD** **Page 2: [1] Comment [S27]**

and medicines, performing biological diagnostics, and conducting public health research (Lesage, 2025). Its bacteriology unit, recognized as a benchmark for antimicrobial resistance surveillance in Guinea, is equipped to diagnose bacterial infectious diseases. In addition, it conducts external quality assessments of bacteriology laboratories nationwide and provides professional training and coaching for laboratory staff.

20/09/2025 05:12:00 **SSD** **Page 2: [2] Comment [S28]**

Institute (INSP), the University Hospital Center Donka, and the Biomedical Laboratory Biomar-24. These laboratories were chosen because they are equipped with the automated VITEK 2 Compact platform for bacterial identification and antimicrobial susceptibility testing. Regional laboratories lacking this automated system were not included in the study.

20/09/2025 05:12:00 **SSD** **Page 2: [3] Comment [S29]**

The study included all patients who visited the selected laboratories and were found to be infected with Gram-negative non-fermentative bacteria during the study period.

20/09/2025 05:13:00 **SSD** **Page 2: [4] Comment [S30]**

All patients who attended the selected laboratories for cyto-bacteriological examination during the study period were included in the study.